Prefusion glycoprotein F0/Pre-F protein (HeV)

Prefusion glycoprotein F0/Pre-F protein (HeV) Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Hendra virus (1)

  • Tag

    His Tag (1)

  • Conjugate

    Unconjugated (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
FUN-H52H4
Hendra virus
HEK293
Hendra virus Pre-Fusion glycoprotein (A263T), His Tag
Total: 1
  • 1

Prefusion glycoprotein F0/Pre-F protein (HeV) Background

Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses discovered in the mid-to late 1990s that possess a broad host tropism and are known to cause severe and often fatal disease in both humans and animals. HeV and NiV infect host cells through the coordinated efforts of two envelope glycoproteins. The G glycoprotein attaches to cell receptors, triggering the fusion (F) glycoprotein to execute membrane fusion. G is a type II homotetrameric transmembrane protein responsible for binding to ephrinB2 or ephrinB3 (ephrinB2/B3) receptors. F is a homotrimeric type I transmembrane protein that is synthesized as a premature F0 precursor and cleaved by cathepsin L during endocytic recycling to yield the mature, disulfide-linked, F1 and F2 subunits. Upon binding to ephrinB2/B3, NiV G undergoes conformational changes leading to F triggering and insertion of the F hydrophobic fusion peptide into the target membrane. Subsequent refolding into the more stable post-fusion F conformation drives merger of the viral and host membranes to form a pore for genome delivery to the cell cytoplasm.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
NangibotideLR-12Phase 2 ClinicalInotremShock, Septic; Coronavirus Disease 2019 (COVID-19)
Details
CEL383CEL-383Phase 1 ClinicalCelsius Therapeutics IncInflammatory Bowel Diseases
Details
ABBV-8736ABBV-8736Phase 1 ClinicalAbbvie IncInflammatory Bowel Diseases
Details
TREM 1 antibody(Boehringer Ingelheim International Gmbh)TREM 1 antibody(Boehringer Ingelheim International Gmbh)Phase 1 ClinicalBoehringer Ingelheim International GmbhImmune System Diseases
Details
PY-159PY-159Phase 1 ClinicalCentre for the Commercialization of Antibodies and BiologicsSolid tumours; Neoplasms
Details
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland